The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to two gene therapies that M6P Therapeutics is developing — one intended for Gaucher disease, the other aiming to treat the inherited metabolic disorder mucolipidosis.
The regulatory agency also awarded six rare pediatric disease designations to various investigational therapies that M6P Therapeutics is developing to treat lysosomal storage disorders, which include Gaucher and mucolipidosis.
“We are grateful to the FDA for these multiple orphan and rare pediatric disease designations that highlight the need for new and improved therapies to address unmet needs,” Pawel Krysiak, president and CEO of M6P Therapeutics, said in a press release.
Lysosomal storage disorders are conditions in which the function of the lysosome — necessary for cell maintenance — is impaired due to missing or defective enzymes. These conditions usually result from mutations in the genes that code for those enzymes. Often described as the cellular “garbage disposal” or “recycling machinery,” lysosomes are responsible for breaking down certain cellular products.
In these disorders, lysosomes do not work properly, causing cellular components to build up to toxic levels. For example, in Gaucher disease, a lack of the lysosomal enzyme beta-glucocerebrosidase leads to a buildup of the cellular component glucocerebroside.
Mannose 6-phosphate, or M6P, is a small sugar molecule that can be attached to lysosomal enzymes. The company’s approach of increasing the mannose 6-phosphate content of gene therapies or enzyme replacement therapies is meant to improve treatment delivery into lysosomes by binding to specific receptors.
Disclaimer: BioPharma Global is not responsible for, and expressly disclaims all liability for, damages of any kind arising out of use,
BioPharma Global is a mission-driven corporation, operating like a not-for-profit, dedicated to using our FDA and EMA regulatory expertise and knowledge of various therapeutic areas to help drug developers advance treatments for the disease communities with a high unmet medical need. If you are a drug developer seeking regulatory support for Orphan Drug designation, Fast Track designation, Breakthrough Therapy designation, other FDA/EMA expedited programs, type A, B (pre-IND, EOPs), or C meeting assistance, or IND filings, the BioPharma Global team can help. Contact us today to arrange a 30-minute introductory call.
Stock image by @everythingposs from Depositphotos